HC Wainwright Reaffirms Buy Rating for Paratek Pharmaceuticals (NASDAQ:PRTK)

Share on StockTwits

Paratek Pharmaceuticals (NASDAQ:PRTK)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a note issued to investors on Sunday, AnalystRatings.com reports. They presently have a $27.00 price objective on the specialty pharmaceutical company’s stock.

PRTK has been the topic of a number of other research reports. Zacks Investment Research cut Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 10th. ValuEngine raised Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Paratek Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $17.30.

PRTK stock traded down $0.10 during midday trading on Friday, reaching $3.14. The company had a trading volume of 4,628 shares, compared to its average volume of 513,582. The company has a quick ratio of 11.83, a current ratio of 12.17 and a debt-to-equity ratio of 14.48. The stock has a 50 day moving average price of $4.13 and a 200 day moving average price of $4.30. Paratek Pharmaceuticals has a fifty-two week low of $2.87 and a fifty-two week high of $9.82. The firm has a market capitalization of $106.37 million, a PE ratio of -0.88 and a beta of 1.76.

Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($1.02) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.16) by $0.14. The company had revenue of $2.05 million during the quarter, compared to the consensus estimate of $1.86 million. Paratek Pharmaceuticals had a negative return on equity of 459.96% and a negative net margin of 597.22%. Research analysts predict that Paratek Pharmaceuticals will post -4.32 EPS for the current year.

In other news, CEO Evan Loh sold 16,265 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $3.98, for a total transaction of $64,734.70. Following the sale, the chief executive officer now owns 413,935 shares of the company’s stock, valued at $1,647,461.30. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Randall B. Brenner sold 7,674 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $3.98, for a total value of $30,542.52. Following the sale, the insider now directly owns 91,338 shares in the company, valued at approximately $363,525.24. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 37,079 shares of company stock worth $145,472. Corporate insiders own 7.70% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of Montreal Can raised its holdings in shares of Paratek Pharmaceuticals by 503.1% during the second quarter. Bank of Montreal Can now owns 7,816 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 6,520 shares during the last quarter. Alambic Investment Management L.P. bought a new stake in Paratek Pharmaceuticals during the second quarter worth approximately $82,000. A.R.T. Advisors LLC bought a new stake in Paratek Pharmaceuticals during the second quarter worth approximately $121,000. Susquehanna International Group LLP raised its holdings in Paratek Pharmaceuticals by 33.0% during the second quarter. Susquehanna International Group LLP now owns 32,060 shares of the specialty pharmaceutical company’s stock worth $128,000 after purchasing an additional 7,960 shares in the last quarter. Finally, Citadel Advisors LLC raised its holdings in Paratek Pharmaceuticals by 7.2% during the second quarter. Citadel Advisors LLC now owns 114,250 shares of the specialty pharmaceutical company’s stock worth $456,000 after purchasing an additional 7,639 shares in the last quarter. 71.28% of the stock is currently owned by institutional investors.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

See Also: What is the significance of the death cross?

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Spirax-Sarco Engineering  Stock Rating Reaffirmed by Morgan Stanley
Spirax-Sarco Engineering Stock Rating Reaffirmed by Morgan Stanley
Arcus Biosciences’  Buy Rating Reiterated at Mizuho
Arcus Biosciences’ Buy Rating Reiterated at Mizuho
JPMorgan Chase & Co. Lowers Varex Imaging  Price Target to $32.00
JPMorgan Chase & Co. Lowers Varex Imaging Price Target to $32.00
STMicroelectronics  – Analysts’ Weekly Ratings Changes
STMicroelectronics – Analysts’ Weekly Ratings Changes
Cyren  Posts  Earnings Results, Beats Estimates By $0.01 EPS
Cyren Posts Earnings Results, Beats Estimates By $0.01 EPS
BlackRock World Mining Trust Plc Plans Dividend of GBX 4
BlackRock World Mining Trust Plc Plans Dividend of GBX 4


© 2006-2019 Ticker Report